Loading…
Abrdn Life Sciences Investors is projected to rise to $24.74 by 2027, a +30% move from its current price of $19.10. HQL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $18.89 | $19.11 | $19.33 | +0.04% |
| Aug 3 | $18.80 | $19.11 | $19.43 | +0.08% |
| Aug 4 | $18.74 | $19.12 | $19.51 | +0.12% |
| Aug 5 | $18.69 | $19.13 | $19.58 | +0.16% |
| Aug 6 | $18.65 | $19.14 | $19.64 | +0.19% |
| Aug 7 | $18.61 | $19.14 | $19.69 | +0.23% |
| Aug 8 | $18.57 | $19.15 | $19.75 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.57 | $19.15 | $19.75 | +0.27% |
| Week 2 | $18.39 | $19.20 | $20.05 | +0.55% |
| Week 3 | $18.26 | $19.26 | $20.31 | +0.82% |
| Week 4 | $18.16 | $19.31 | $20.53 | +1.10% |
| Week 5 | $18.08 | $19.36 | $20.73 | +1.37% |
| Week 6 | $18.01 | $19.41 | $20.93 | +1.65% |
| Week 7 | $17.95 | $19.47 | $21.11 | +1.92% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe and seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies and employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio.
The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Abrdn Life Sciences Investors trades under the symbol HQL. It has a current price of $19.44 with a market capitalization of $591.13M and a rank of 2722. The current price provides the baseline for the forecasted path ahead.
The 2026 forecast shows an average price of $19.44 with a range from $15.87 to $25.51 and an expected ROI of 0% with a Neutral outlook. The forecast extends through 2035 with increasingly bullish exposures and rising averages, culminating in a 2050 average of $213.70 and an ROI of 999.3% with a bullish sentiment.
A major floor 16.7% below — a decisive break under it would weaken the trend.
The nearest floor, 6.0% below — buyers have tended to step in here.
The nearest ceiling, 9.1% above — a clean break opens room to run.
A major ceiling 16.1% above — clearing it would confirm fresh momentum.
Key HQL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HQL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.29 | Sell | $19.29 | Sell |
| MA 10 | $19.44 | Sell | $19.43 | Sell |
| MA 20 | $19.81 | Sell | $19.45 | Sell |
| MA 50 | $18.65 | Buy | $18.92 | Buy |
| MA 100 | $17.94 | Buy | $18.24 | Buy |
| MA 200 | $17.42 | Buy | $17.31 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.63 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -121.84 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -5.21 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 33.65 | Neutral |
| Momentum (10) | -0.64 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 19.20 | Sell |
| ADX (14) | 19.20 | Neutral |
| ATR (14) | 0.22 | Info |
The 30-day technical picture is bullish with RSI14 at 50. The stock trades above key moving averages, with SMA50 at $18.62 and SMA200 at $17.41. Support is listed at $17.86 and resistance at $20.83, framing a 30-day range of $18.04 to $20.94. Annualized volatility stands at 20%, indicating notable but manageable swings within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.87 | $19.10 | $25.03 | 0% | Neutral | |
| $20.29 | $24.74 | $31.53 | +30% | Bullish | |
| $22.05 | $27.40 | $35.88 | +43% | Bullish | |
| $23.96 | $30.24 | $40.45 | +58% | Bullish | |
| $25.63 | $32.79 | $44.66 | +72% | Bullish | |
| $30.10 | $38.97 | $53.92 | +104% | Bullish | |
| $36.28 | $47.52 | $66.69 | +149% | Bullish | |
| $39.48 | $52.26 | $74.29 | +174% | Bullish | |
| $44.64 | $59.68 | $85.85 | +212% | Bullish | |
| $46.67 | $62.98 | $91.61 | +230% | Bullish | |
| $75.69 | $106.54 | $162.44 | +458% | Bullish | |
| $133.56 | $201.64 | $329.58 | +956% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $15.87 | $19.10 | $22.85 | +0.00% |
| September 2026 | $16.35 | $19.17 | $22.98 | +0.35% |
| October 2026 | $16.80 | $19.79 | $23.91 | +3.25% |
| November 2026 | $17.28 | $20.43 | $24.83 | +3.23% |
| December 2026 | $17.26 | $20.48 | $25.03 | +0.25% |
Click any year to see its month-by-month HQL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, HQL is projected to trade between $15.87 and $25.03, averaging $19.10 — a potential gain of 0% from today's $19.10. Price action looks broadly range-bound.
Abrdn Life Sciences Investors's 2027 outlook centres on $24.74, within a $20.29 to $31.53 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, HQL could reach as high as $35.88, with a base case around $27.40 and support toward $22.05 — roughly +43% from $19.10. Momentum favours further upside here.
Expect HQL to range from $23.96 to $40.45 through 2029. The $30.24 average target implies a +58% move from current prices. That is up +10% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The HQL price prediction for 2030 points to an average of $32.79 (low $25.63, high $44.66) — a potential gain of +72% on today's $19.10. Momentum favours further upside here.
In 2031, HQL is projected to trade between $30.10 and $53.92, averaging $38.97 — a potential gain of +104% from today's $19.10. That is up +19% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Abrdn Life Sciences Investors's 2032 outlook centres on $47.52, within a $36.28 to $66.69 range. That is up +22% on the projected 2031 average. That marks a +149% change versus current levels. Momentum favours further upside here.
By 2033, HQL could reach as high as $74.29, with a base case around $52.26 and support toward $39.48 — roughly +174% from $19.10. Buyers look set to stay in control over this stretch.
Expect HQL to range from $44.64 to $85.85 through 2034. The $59.68 average target implies a +212% move from current prices. That is up +14% on the projected 2033 average. Momentum favours further upside here.
The HQL price prediction for 2035 points to an average of $62.98 (low $46.67, high $91.61) — a potential gain of +230% on today's $19.10. Buyers look set to stay in control over this stretch.
In 2040, HQL is projected to trade between $75.69 and $162.44, averaging $106.54 — a potential gain of +458% from today's $19.10. That is up +69% on the projected 2035 average. Momentum favours further upside here.
Abrdn Life Sciences Investors's 2050 outlook centres on $201.64, within a $133.56 to $329.58 range. That is up +89% on the projected 2040 average. That marks a +956% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in HQL today (≈ 52.356021 HQL) could be worth
$10,556.92
+$9,556.92 (+956%) by 2050 · US Dollar
Based on the average projected HQL price of $201.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HQLwould be worth at today's price.
$1,000 invested in HQL on Jul 31, 2025 (≈ 76.161462 HQL) would be worth
$1,454.68
+$454.68 (+45.5%) today · 1.45× · US Dollar
Based on a HQL entry price of $13.13 vs. today's $19.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.25 | $992.21 | -0.8% |
| 1 month ago | $19.98 | $955.96 | -4.4% |
| 3 months ago | $17.55 | $1,088.32 | +8.8% |
| 6 months ago | $17.16 | $1,113.05 | +11.3% |
| 1 year ago | $13.13 | $1,454.68 | +45.5% |
| All time (5.0y) ago | $20.97 | $910.83 | -8.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HQL forecast.
Our base-case forecast reaches $38.00 around 2031.
Implied market cap at $38.00: $1.16B
The multi-year forecast shows a strong upward path. By 2030 the average price is projected at $33.92 with a min of $26.52, a max of $46.20 and an ROI of 74.5% in a bullish context. The forecast climbs further across the decade, with 2040 averaging $111.99 and an ROI of 476.1% and a 2050 average of $213.70 with an ROI of 999.3%—both still marked as bullish.
These figures imply substantial upside over the long horizon, though they remain estimates, not guarantees.
Tap a question to reveal the answer.
Avg $33.92, min $26.52, max $46.20, ROI 74.5%, sentiment BULLISH.
Forecasts show bullish sentiment with rising averages and high ROI by 2050 (avg $213.70, ROI 999.3%), but these are estimates and not guaranteed.
Yes, the forecasted max values include $95.63 in 2035 and $170.74 in 2040, so surpassing $100 is projected by 2040.
Low $18.04, high $20.94.
Current price $19.44; market cap $591.13M.
Abrdn Life Sciences Investors Community Discussion
0Share your Abrdn Life Sciences Investors price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.